CXI Healthcare Technology Group (900120) Fair Value & Analysis
Healthcare · KR · Market cap 40.7B KRW
Fair value as of: Jul 21, 2026
From 24 valuation models · updated today
Price vs Fair Value (12 months)
12‑month range 1,042 KRW – 4,600 KRW · fair‑value band 136.75 KRW – 283.98 KRW · the 1,081 KRW price screens above the 202.36 KRW fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CXI Healthcare Technology Group (900120) currently trades at 1,081 KRW, while our model-based Fair Value estimate is 202.36 KRW, implying the stock looks roughly 81.3% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, CXI Healthcare Technology Group generated revenue of 51.4B KRW at a net margin of 16.8%. Revenue declined 27.5% year over year. It earns a return on equity of 1.6%. Fundamentals as of Jul 21, 2026
Our scenario range runs from 136.75 KRW (bear case) to 283.98 KRW (bull case); at 1,081 KRW, the current price sits above that range. The share trades about 4% below its 52-week high and 234% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -81%, 900120 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
CXI Healthcare Technology Group Limited engages in the manufacture and distribution of health foods. It provides Chinese medicine-based health supplements in capsule, tablet, drink, and tea forms. The company was formerly known as CKH Food & Health Limited and changed its name to CXI Healthcare Technology Group Limited in October 2023. CXI Healthcare Technology Group Limited was founded in 2009 and is based in Grand Cayman, the Cayman Islands.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
CXI Healthcare Technology Group reported revenue of 377M KRW in FY2024 versus 373M KRW in FY2020, a compound +0.3%/yr. Reported net income was 159M KRW in FY2024.
Is 900120 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
| Mankind Pharma Limited MANKIND | ₹2,336 | ₹1,068 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CXI Healthcare Technology Group (900120) undervalued?
What is the fair value of 900120?
What is the quality score of 900120?
What is the revenue of CXI Healthcare Technology Group (900120)?
What is the net profit margin of 900120?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when CXI Healthcare Technology Group reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of CXI Healthcare Technology Group materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.